Overview
Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.
Principal investigator
Eligibility criteria
Inclusion Criteria:
- had preeclampsia in the past 5 years,
- 18 years or older
Exclusion criteria:
- current daily aspirin use,
- skin diseases,
- current tobacco or nicotine use (including vaping),
- diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR < 60 mL/min/1.73m2,
- statin or other cholesterol-lowering medication,
- current antihypertensive medication,
- history of hypertension prior to pregnancy,
- history of gestational diabetes,
- currently pregnancy,
- body mass index <18.5 kg/m2,
- allergy to materials used during the experiment.(e.g. latex),
- known allergies to study drugs,
- bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).
Participate in this trial
Are you interested in enrolling in this study? Learn more here.
I'm Interested In ParticipatingFor Referring Providers
Do you have a patient you think would be a good candidate for this trial? Learn more about enrolling your patient.